Clinical TrialJun 1, 2026, 07:26 AM
Molecular Partners Dosing Patients in Phase 1 MP0712 Trial; Presents at ASCO/SNMMI
AI Summary
Molecular Partners announced it is actively dosing patients in the first cohort of its Phase 1/2a study for MP0712, a DLL3-targeting Radio-DARPin Therapy for small cell lung cancer and other neuroendocrine cancers. The company will present trial-in-progress poster presentations on the study at the 2026 American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meetings. Initial clinical data from this study is expected later in 2026, building on prior diagnostic imaging data that showed specific tumor uptake.
Key Highlights
- Molecular Partners is actively dosing patients in the first cohort of its Phase 1/2a study for MP0712.
- Trial-in-progress poster presentations on MP0712 will be held at ASCO (May 29-June 2) and SNMMI (May 30-June 2) 2026.
- MP0712 is a 212Pb-based Radio-DARPin Therapy targeting DLL3 for small cell lung cancer (SCLC) and neuroendocrine cancers.
- DLL3 is expressed in over 85% of SCLC tumors, making it a highly relevant target.
- Initial clinical data from the Phase 1/2a study is expected to be shared in 2026.
- Previous data from January 2026 showed specific tumor uptake with a diagnostic isotope, supporting clinical plans.
Price Impact
More from MOLN